Greenland Mines Ltd. Common Stock
GRMLАкція
$0.25
Капіталізація$29.01M
P/E—
Див. дохідність—
Бета1.53
Графік ціни
Улюблені метрики
Ціна відносно S&P 500 (4 тиж.)-34.42%
Загальна оцінка (VGM)9.73
Ринкова капіталізація$29.01M
Порівняння з галуззю — Біологічні препарати(180)
| Символ | Оцінка недооціненості | Оцінка зростання | Оцінка моментуму | Ціна |
|---|---|---|---|---|
GRMLGreenland Mines Ltd. Common Stock | — | — | F | $0.25 |
| AMGNAmgen Inc | C | C | C | $357.09 |
| GILDGilead Sciences Inc | C | B | C | $126.49 |
| ARGXargenx SE American Depositary Shares | D | A | B | $884.85 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $213.72 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $89.50 |
| MRNAModerna, Inc. Common Stock | D | B | B | $66.57 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $166.91 |
| EXELExelixis Inc | C | B | B | $54.40 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $365.21 |
Про акцію
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.